StreetInsider.com News Articles

Form 4 PALISADE BIO, INC. For: Jul 08 Filed by: Baltera Robert Jr.

Fri, 10 Jul 2026 18:14:00 -0400

si-local-file:///var/storage/secattach/20260710/26758186.html

Form 4 PALISADE BIO, INC. For: Jul 08 Filed by: Baltera Robert Jr.

Fri, 10 Jul 2026 18:14:00 -0400

si-local-file:///var/storage/secattach/20260710/26758186.html

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Fri, 10 Jul 2026 09:00:00 -0400

Management to participate in investor meetings on July 14-15 in Boston

Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-15, 2026, in Boston, Massachusetts.

Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical development strategy,

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Fri, 10 Jul 2026 09:00:00 -0400

Management to participate in investor meetings on July 14-15 in Boston

Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical development strategy,

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Fri, 10 Jul 2026 09:00:00 -0400

Management to participate in investor meetings on July 14-15 in Boston

Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical development strategy,

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Fri, 10 Jul 2026 09:00:00 -0400

Management to participate in investor meetings on July 14-15 in Boston

Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical development strategy,

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Baltera Robert Jr.

Wed, 08 Jul 2026 18:56:00 -0400

si-local-file:///var/storage/secattach/20260708/26748611.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Baltera Robert Jr.

Wed, 08 Jul 2026 18:56:00 -0400

si-local-file:///var/storage/secattach/20260708/26748611.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Jones Mitchell Lawrence

Wed, 08 Jul 2026 18:53:00 -0400

si-local-file:///var/storage/secattach/20260708/26748599.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Jones Mitchell Lawrence

Wed, 08 Jul 2026 18:53:00 -0400

si-local-file:///var/storage/secattach/20260708/26748599.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Finley John David

Wed, 08 Jul 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260708/26748593.html

Form 4 PALISADE BIO, INC. For: Jul 06 Filed by: Finley John David

Wed, 08 Jul 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260708/26748593.html

Form 144 PALISADE BIO, INC. Filed by: Jones Mitchell Lawrence

Tue, 07 Jul 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260707/26742710.html

Form 144 PALISADE BIO, INC. Filed by: Jones Mitchell Lawrence

Tue, 07 Jul 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260707/26742710.html

Form 144 PALISADE BIO, INC. Filed by: Finley John David

Tue, 07 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260707/26742528.html

Form 144 PALISADE BIO, INC. Filed by: Finley John David

Tue, 07 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260707/26742528.html

Form 4 PALISADE BIO, INC. For: Jul 01 Filed by: Baltera Robert Jr.

Mon, 06 Jul 2026 19:48:00 -0400

si-local-file:///var/storage/secattach/20260706/26737095.html

Form 4 PALISADE BIO, INC. For: Jul 01 Filed by: Baltera Robert Jr.

Mon, 06 Jul 2026 19:48:00 -0400

si-local-file:///var/storage/secattach/20260706/26737095.html

H.C. Wainwright Reiterates Buy Rating on Palisade Bio Inc. (PALI)

Tue, 30 Jun 2026 06:45:41 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $7.00 price target on Palisade Bio Inc. (NASDAQ: PALI).

The analyst commented: "Palisade Bio announced FDA IND clearance for the global Phase 2 ASCENTRA-UC trial of PALI-2108 in ulcerative colitis (UC), with enrollment expected to begin in 2H26 and primary efficacy data expected in 2H27. The ASCENTRA-UC trial is slated to enroll up to 204 moderate-to-severe UC patients randomized to once-daily 15mg PALI-2108, 30mg PALI-2108, or placebo for 12 weeks, with clinical remission by modified Mayo Score as the primary endpoint and a 36-week maintenance period to assess durability through

Palisade Bio gets FDA clearance to begin Phase 2 UC drug trial

Mon, 29 Jun 2026 08:30:53 -0400

Palisade Bio, Inc. (NASDAQ: PALI) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for PALI-2108, an oral PDE4 inhibitor prodrug candidate for inflammatory bowel disease, allowing the company to proceed with a global Phase 2 clinical trial in ulcerative colitis.

The trial, called ASCENTRA-UC, is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study expected to enroll approximately 204 patients with moderately to severely active ulcerative colitis across sites in North America and Europe. The study will evaluate two once-daily dose levels of PALI-2108, 15 mg and 30 mg, compared with placebo.

The primary endpoint is clinical

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Mon, 29 Jun 2026 08:30:00 -0400

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe

First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027

IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio

Denver, CO, June 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Mon, 29 Jun 2026 08:30:00 -0400

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe

First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027

IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Mon, 29 Jun 2026 08:30:00 -0400

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe

First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027

IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Mon, 29 Jun 2026 08:30:00 -0400

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe

First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027

IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio

Form 4 PALISADE BIO, INC. For: Jun 10 Filed by: Baltera Robert Jr.

Thu, 18 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260618/26666070.html